Liraglutide's effect on liver fat content and lipoprotein metabolism to be assessed in type 2 diabetes patients
Background
Non-alcoholic fatty liver disease (NAFLD) is frequently linked to obesity, metabolic syndrome, and type 2 diabetes, leading to lipid abnormalities like hypertriglyceridemia and decreased HDL-cholesterol, which increase cardiovascular risk. NAFLD also carries a 3-5% risk of progressing to cirrhosis. While animal studies show liraglutide reduces liver fat, its effect in human type 2 diabetes patients remains unknown, as do the mechanisms behind its observed plasma lipid modifications. This study aims to bridge these gaps.
Study Design
This monocentric study will administer Liraglutide 1.2 mg/day for 6 months to type 2 diabetes patients. Liver fat content will be measured by proton-spectroscopy in n=120 patients at baseline and after treatment. Additionally, an in vivo kinetic study using stable isotopes (13C leucine) will assess lipoprotein metabolism in n=10 of these patients, involving a 2-day hospitalization before and after the 6-month therapy.
Why It Matters
Crucial insights into liraglutide's potential beyond glycemic control, specifically its impact on liver fat and lipoprotein metabolism in type 2 diabetes, are expected from this research. If successful, it could solidify liraglutide's role in managing NAFLD and associated dyslipidemia, offering a dual benefit for patients. Understanding the mechanisms of lipid modification could optimize treatment strategies and potentially lead to new combination therapies. The use of gold-standard methods (proton-spectroscopy and stable isotope kinetics) ensures high-quality data, which is vital for translating findings into clinical practice and refining existing protocols for liraglutide use.
liraglutide
type 2 diabetes
nafld
fatty liver
lipoprotein metabolism
clinical trial